PET scans for Dementia

A Primer for Patients and Caregivers.

FDG PET-CT is available in 7/10 provinces in Canada for the assessment of dementia (see detailed report).

It’s indications are outlined and endorsed by guidance statements published by the Canadian Consensus conference on the diagnosis and treatment of dementia available here.

Functional Imaging with PET is used to assist with the diagnosis of specific forms of dementia when the clinical diagnosis is unclear.

Why does this matter to patients?

There was a time when having this information would not have changed management of patients as we had nothing to offer them. At this point, paying for this test may not have been a high priority.

In 2026, we have many new and emerging drugs that target specific pathways like amyloid plaque buildup such as recently Health Canada approved Lecanemab.

Amyloid PET plays a key role in appropriate diagnosis in these patients, and is also the only validated means of assessing treatment response and change in amyloid plaque burden.

FDG PET is a test using radioactive sugar that is essential in the diagnosis of other dementias that can mimic Alzheimer’s or occur together as mixed disease. Misdiagnosis of Alzheimer’s mimics can lead to serious complications on some Alzheimer’s medications.

Do Clinicians See Value?

Quebec has been doing PET for dementia for over 20 years, and it is a robust part of the clinical evaluation of patients. Listen to a recent webinar from a Canadian Leader Karine Provost from Universite de Montreal on how a modern dementia PET program operates.

What can I do to improve access to this test?

Let politicians and decisionmakers know this is important to you.


Response

Leave a Reply